Can-Fite BioPharma Ltd. (TASE: CANF)
Health Care · Biotechnology · IL
₪3.04
-3.00% today · -89.9% 1Y
Can-Fite BioPharma Ltd. (TASE: CANF) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.94M and employs 5 people.
Over the last twelve months the share price has lost 89.9%, trading between 2.99 and 30.00.
Tweenvest scores Can-Fite BioPharma Ltd. across four factors: quality 43/100, value 36/100, growth 0/100. Its strongest factor is quality.
CANF price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.94M
- Revenue (TTM)
- $405.00K
- P/E
- —
- EPS
- -3.26
- Dividend yield
- —
- Beta (5Y)
- -0.02
- 52-week high
- ₪30.00
- 52-week low
- ₪2.99
- Avg volume (3M)
- —
- Shares outstanding
- 6.06M
- Employees
- 5
- Next earnings
- —
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.
- ISIN
- IL0010944739
- Founded
- 1994
- Listed since
- Oct 6, 2005
- Exchange
- The Tel-Aviv Stock Exchange
- Currency
- ILS
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Evogene Ltd.TASE: EVGN | $6.08M | ₪1.19 | -2.69% |
| Bio Green Med Solution, Inc.NasdaqCM: BGMS | $6.02M | $0.91 | +7.10% |
| Acurx Pharmaceuticals, Inc.NasdaqCM: ACXP | $5.98M | $1.14 | -0.44% |
| Niki BioSolutions, Inc.NasdaqCM: NIKI | $5.97M | $2.03 | -49.25% |
| Cizzle Biotechnology Holdings PlcLSE: CIZ | $5.81M | £0.01 | -29.31% |
| OLIPASS CorporationKOSDAQ: A244460 | $5.72M | ₩— | — |
| Imunon, Inc.NasdaqCM: IMNN | $5.72M | $1.02 | -5.56% |
| AquaBounty Technologies, Inc.NasdaqCM: AQB | $5.71M | $1.11 | +8.82% |
Figures last refreshed Oct 18, 2026.